118th Congress · HOUSE BILLBILL

H.R. 3810Drug Origin Transparency Act of 2023

To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.

Health
Introduced Jun 5, 2023
Last action Jun 9, 2023
Pipeline · Bill → Law
Step 1
Introduced
Jun 5, 2023
Step 2
Referred
Jun 9, 2023
E&C
Step 3
Committee
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary

This bill requires drug manufacturers to report on the suppliers of ingredients used in their products. Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.

Provisions · 3 sectionsIntroduced in House
Timeline · 3 actions
Jun 9, 2023
Referred to the Subcommittee on Health.
Jun 5, 2023
Introduced in House
Jun 5, 2023
Referred to the House Committee on Energy and Commerce.